Claims for Patent: 10,888,605
✉ Email this page to a colleague
Summary for Patent: 10,888,605
Title: | GLP-1 compositions and uses thereof |
Abstract: | The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof. |
Inventor(s): | Moeller; Eva Horn (Alleroed, DK), Soerensen; Michael Duelund (Soeborg, DK), Lundqvist; Joakim (Malmoe, SE) |
Assignee: | Novo Nordisk A/S (Bagsvaerd, DK) |
Application Number: | 16/774,666 |
Patent Claims: |
1. A liquid pharmaceutical composition comprising semaglutide and phenol, wherein said composition (a) is for parenteral administration; (b) is an aqueous solution
comprising at least 60% w/w) water; or (c) further comprises one or more pharmaceutically acceptable excipients selected from the group consisting of a buffer or an isotonic agent; wherein the semaglutide is in the range of 0.5 mg/ml-5.0 mg/ml;
wherein the phenol is no more than 0.1 mg/ml; and wherein the pH of the composition is in between 7.0 and 7.8.
2. The composition according to claim 1, wherein said composition comprises one or more pharmaceutically acceptable excipients. 3. The composition according to claim 2, wherein said one or more pharmaceutically acceptable excipients are selected from the group consisting of a buffer or an isotonic agent. 4. The composition according to claim 3, wherein said buffer is a phosphate buffer. 5. The composition according to claim 3, wherein said isotonic agent is selected from propylene glycol or sodium chloride. 6. The composition according to claim 1, wherein said composition comprises no preservative. 7. The composition according to claim 1, wherein said composition has a pH in the range of 7.0-7.4. 8. The composition according to claim 1, wherein said parenteral administration is subcutaneous administration. 9. The composition according to claim 1, wherein said composition comprises 0.5 mg/ml-5.0 mg/ml semaglutide, propylene glycol and 1.42 mg/ml disodiumhydrogenphosphate dihydrate. 10. The composition according to claim 1, wherein said composition comprises 0.5 mg/ml-5.0 mg/ml semaglutide, sodium chloride and 1.42 mg/ml disodiumhydrogenphosphate dihydrate. 11. A kit comprising a liquid pharmaceutical composition of claim 1 and instructions for use. 12. A kit comprising a liquid pharmaceutical composition of claim 1 and an injection device for administration of said composition to a subject, wherein said injection device is selected from the group consisting of a durable pen and a prefilled pen. 13. A method of treating diabetes comprising administering to a subject in need of such treatment a therapeutically effective amount of a composition according to claim 1. 14. A method of treating obesity comprising administering to a subject in need of such treatment a therapeutically effective amount of a composition according to claim 1. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.